Dublin, Feb. 06, 2018 -- The "Swine and Avian Influenza Drug Development Pipeline Review, 2017" report has been added to ResearchAndMarkets.com's offering.
H5N1 is a type of influenza virus that causes a highly infectious, severe respiratory disease in birds called avian influenza. This virus can spread to humans. There are a total of 63 products in development for this indication, by 47 companies and six academic institutions. Key companies operating in this pipeline space include Gemmus Pharma, Aphios, Fides Pharma, Inovio Pharmaceuticals, Microbiotix, NanoViricides, Shionogi, the University of Wisconsin Madison and Tria Bioscience.
H1N1 Infection also called as swine flu is a new kind of flu in humans. It's caused by the contagious H1N1 influenza virus. There are a total of 99 products in development for this indication, by 67 companies and 14 academic institutions. Key companies operating in this pipeline space include Johnson & Johnson, and the University of Sherbrooke.
In both types of influenza, the most common molecular target being studied is hemagglutinin, by a considerable margin. However, a number of both human and viral proteins are also under active development.
This report provides an overview of the Swine and Avian Influenza pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for influenza A virus, subtypes H5N1 and H1N1, and features dormant and discontinued projects. Symptoms of influenza include fever and cough, fatigue, acute respiratory distress, shortness of breath, abdominal pain and diarrhea.
Scope
- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?
Key Topics Covered:
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Swine and Avian Influenza Report Coverage
2.2 Influenza A Virus, H5N1 Subtype Infections - Overview
2.3 Influenza A Virus, H1N1 Subtype Infections - Overview
3 Therapeutics Development
3.1 Influenza A Virus, H5N1 Subtype Infections
3.2 Influenza A Virus, H1N1 Subtype Infections
4 Therapeutics Assessment
4.1 Influenza A Virus, H5N1 Subtype Infections
4.2 Influenza A Virus, H1N1 Subtype Infections
5 Companies Involved in Therapeutics Development
5.1 Influenza A Virus, H5N1 Subtype Infections
5.2 Influenza A Virus, H1N1 Subtype Infections
6 Dormant Projects
6.1 Influenza A Virus, H5N1 Subtype Infections
6.2 Influenza A Virus, H1N1 Subtype Infections
7 Discontinued Products
7.1 Influenza A Virus, H5N1 Subtype Infections
7.2 Influenza A Virus, H1N1 Subtype Infections
8 Product Development Milestones
8.1 Influenza A Virus, H5N1 Subtype Infections
8.2 Influenza A Virus, H1N1 Subtype Infections
9 Appendix
For more information about this report visit https://www.researchandmarkets.com/research/83sl8p/global_swine_and?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Discovery, Infectious Diseases Drugs, Animal Healthcare/Veterinary


SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Instagram Outage Disrupts Thousands of U.S. Users
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 



